Program
Drugs, Investigational
Also written as “Investigational drug”, “Investigational new drug, company code: BGG492” and “TimoD implant”.
Its studies are mostly in Keratosis, Actinic · Glaucoma · Burns · Glaucoma, Open-Angle · Nervous System Diseases, led by 7 companies.
Drug pageDrugs, Investigational: every studyMany companies study it; this page follows only the 10 they lead. All 14 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| EyeD Pharmaits history only | 21 open or running | phase 2since Jun 17, 2025 | Mar 13, 2024 | Jan 2027phase 2 · NCT07036510 |
| Novartisits history only | 20 open or running | phase 2since Apr 23, 2009 | Apr 23, 2009 | none ahead |
| Pfizer | 20 open or running | phase 2since May 2, 2002 | May 2, 2002 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 2since Jun 26, 2002 | Jun 26, 2002 | none ahead |
| Merckits history only | 10 open or running | phase 3since Aug 25, 2000 | Aug 25, 2000 | none ahead |
| Skingenixits history only | 11 open or running | phase 2since Feb 14, 2011 | Feb 14, 2011 | Dec 31, 2026phase 2 · NCT01297400 |
| Sun Pharmaceutical Industriesits history only | 11 open or running | phase 1since Jul 22, 2026 | Jul 22, 2026 | Dec 2026phase 1 · NCT07729579 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 2, 2002First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT00034957 · United States
- May 8, 2002Phase 1 study in Multiple MyelomaNCT00036140 · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00036140Multiple Myeloma · United States | 1 | Completed | ||
| NCT00034957Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Oct 2002 |
How it is read
Names in the registry
- “Investigational drug”, 5 entries
- “Investigational new drug, company code: BGG492”, 3 entries
- “TimoD implant”, 2 entries
- “Investigational Drug, MW-III”, 1 entry
Conditions, from the studies’ own filings
- Keratosis, Actinic, 1 study
- Glaucoma, 1 study
- Burns, 1 study
- Glaucoma, Open-Angle, 1 study
- Nervous System Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.